Predictive Biology

Executive Summary

Predictive Biology is a pre-clinical biotechnology company leveraging a proprietary in vitro genetics platform to decode the molecular etiology of complex traits and drug responses. By integrating genetically diverse stem cell models, organoids, and single-cell technologies, the company aims to identify and validate novel drug targets with higher translational success. Founded in 2019 and based in Cambridge, MA, with operations in Carlsbad, CA, Predictive Biology has assembled a strong scientific team and is building a pipeline focused on genetically validated targets. The platform's ability to map genetic modifiers of disease phenotypes and compound action offers a differentiated approach to drug discovery, potentially reducing costly late-stage failures. Despite being in a pre-revenue stage, the company has garnered interest for its innovative methodology and is positioned to address high unmet needs in complex diseases. Key upcoming milestones include securing Series A financing, releasing preclinical proof-of-concept data, and forming strategic partnerships.

Upcoming Catalysts (preview)

• Q2 2026Publication of preclinical validation data in a peer-reviewed journal60% success
• Q3 2026Completion of Series A financing round80% success
• Q1 2027Announcement of a strategic collaboration with a pharmaceutical company40% success